C

Chimerix
D

CMRX

0.93000
USD
-0.09
(-8.37%)
Market Closed
Volume
3,017
EPS
0
Div Yield
0
P/E
-1
Market Cap
83,363,931
Related Instruments
    AZN
    2.040
    (2.58%)
    81.200 USD
    B
    BNTX
    -5.530
    (-6.42%)
    80.570 USD
    GSK
    0.865
    (2.23%)
    39.650 USD
    I
    INO
    -0.670
    (-6.28%)
    10.000 USD
    JNJ
    2.930
    (1.86%)
    160.770 USD
    MRNA
    -25.020
    (-20.99%)
    94.160 USD
    N
    NVAX
    -0.250
    (-1.95%)
    12.560 USD
    PFE
    0.115
    (0.38%)
    30.650 USD
    V
    VIR
    -0.43000
    (-4.22%)
    9.75000 USD
    V
    VXRT
    -0.01170
    (-1.74%)
    0.65890 USD
    More
News

Title: Chimerix

Sector: Healthcare
Industry: Biotechnology
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.